• Nie Znaleziono Wyników

The voice of the editor-in-chief

N/A
N/A
Protected

Academic year: 2022

Share "The voice of the editor-in-chief"

Copied!
2
0
0

Pełen tekst

(1)

1

The Voice of the Editor-in-Chief

Dear Colleagues,

So expected summer holidays are now inevitably coming to an end. Returning to work means new chal- lenges and permanent searching for optimal forms of diagnostics and treatment of diabetes aimed first of all at the reduction of vascular complications of diabetes and, as a consequence, improved quality of life of the patients. Diabetic patients are hospitalized 3-fold more frequently compared with people with- out carbohydrate metabolism disturbances and the risk of mortality is 3–4-fold higher than in remaining population. Chronic hyperglycaemia seems to be a key factor leading to the development and progression of vascular complications of diabetes, besides the impact of genetic predisposition and broadly defined environmental factors such as poor diet, low physical activity and obesity. In type 1 diabetes hyperglycaemia results from absolute insulin deficiency, whereas in type 2 diabetes it is a consequence of a number of processes leading to decreased peripheral tissue sen- sitivity to insulin (mainly muscles and adipose tissue) i.e. insulin resistance and/or dysfunction of pancreatic beta cells causing impaired insulin secretion. Avail- able studies show close association between severity

and duration of blood glucose elevation and the risk of chronic vascular complications of diabetes. These associations have been proven both in type 1 and type 2 diabetes. Despite recent advances in medicine, introduction of new hypoglycaemic drugs and the fact that more than 3.500 years have passed since the earliest known record of diabetes in Egyptian papyrus dated back to around 1550 B.C., the development of late complications of diabetes, which significantly de- teriorate patients’ quality of life, still remains the most important problem in contemporary diabetology and diabetes itself remains an incurable disease.

A new issue of Clinical Diabetology discusses these topics, both the aspect of vascular complications and available diagnostics and treatment. I hope that this issue of our Journal will support our readers in everyday practice and help them in making clinical decisions. It should be remembered that medicine still remains an art that frequently does not know easy ways and com- pletely anticipated solutions and that the management of diabetes, like the treatment of other human diseases, should be related to maximum benefits for patients and lead to increase in their quality of life.

Editor-in-Chief

Prof. Janusz Gumprecht

(2)

Cytaty

Powiązane dokumenty

Another challenge is effective and safe use of antidiabetic drugs to minimize side effects, improve adherence, increase the acceptance of the disease and reduce the risk

At the beginning of October, annual meeting of European Association for the Study of Diabetes (EASD) will be held in Berlin, and one of the most awaited events during this

Among papers included in this issue of “Clinical Diabetology”, it is worth paying attention to a multi- centre study conducted in 2013–2017 in women with type 1 diabetes who,

As the practical management of patients with diabetes should be based primarily on knowledge derived from Evidence Based Medicine (EBM), the reference to the EBM

I would like to draw your attention to the problem of diabetes care quality discussed by researchers from Libya, an interesting case report of the use of hydroxychloroquine in type

Many interesting reports presented during the Congress addressed, among others, epidemiology, new possibilities of molecular biology, measurable effects of translating basic

Following the publication of the results of already completed Cardiovascular Outcome Trials (CVOTs) on new molecules used in the treatment of diabetes, there is no doubt that

In the InTandem3 study (Study to Evaluate the Safety of So- tagliflozin in Patients With Type 1 Diabetes Who Have Inadequate Glycaemic Control With Insulin Therapy Alone) with